NovoCure Ltd — Director's Dealing 2020

May 7, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2020-05-05

Reporting Person: Shah Pritesh (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-05	Ordinary Shares	S	1149	$62.20	Disposed	100693	Direct

Footnotes

F1: On March 10, 2020, the reporting person filed a Form 4 that included information labeled "Restricted Share Units" in column 1, table 1. All shares reported in that table should have been with respect to "Ordinary Shares" and all information in such Form 4 and all subsequent Form 4 reports refer to Ordinary Shares only.

F2: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah.